Humacyte Provides Commercial Update and Highlights Rapid Acceleration of Symvess Adoption by Hospitals
Key Highlights
- ➤Symvess-ordering hospitals rose 44%, from 34 in Q2 to 49 by September 30, 2026
- ➤Humacyte says new hospital ordering activity increased sequentially each third-quarter month
- ➤Hospital additions could surpass Humacyte’s goal of 20 new hospitals by year-end
- ➤Humacyte says accelerating adoption positions Symvess for substantial growth through 2026
Expert Statements
Jim Mercadante, Chief Commercial Officer of Humacyte
“Our commercial execution is generating strong momentum across the United States and validating the significant unmet need for an off-the-shelf bioengineered vascular conduit,”
Jim Mercadante, Chief Commercial Officer of Humacyte
“The increasing rate of new hospital adoption, growing physician engagement, and expanding utilization highlight the power of the new commercial strategy we set in place in Q2 2026.”
Jim Mercadante, Chief Commercial Officer of Humacyte
“More surgeons are learning about our product, driving increased hospital network engagement and expanding contracts being put in place, translating into strong revenue growth.”
Jim Mercadante, Chief Commercial Officer of Humacyte
“We believe the acceleration we have seen throughout the third quarter positions us for substantial growth throughout the remainder of 2026.”
Benjamin Pearce, Director of the Vascular Surgery Integrated Residency and Fellowship Programs and the William D. Jordan, Jr. Endowed Professor in Vascular Surgery and Endovascular Therapy at the University of Alabama at Birmingham
“Both doctors and patients have been waiting for a technology like this for years. It has the promise of overcoming the limitations of endovascular therapy and where classic non-autogenous conduits fail,”
Benjamin Pearce, Director of the Vascular Surgery Integrated Residency and Fellowship Programs and the William D. Jordan, Jr. Endowed Professor in Vascular Surgery and Endovascular Therapy at the University of Alabama at Birmingham
“In the right patient population, we’ve seen Symvess do very well in reducing risk of infection and rates of amputation. It has become a pivotal part of our treatment algorithm in high-risk patients when autologous vein is not an option.”
Jim Mercadante, Chief Commercial Officer of Humacyte
“We are encouraged by the accelerating commercial momentum for Symvess and look forward to providing further perspective on hospital adoption, surgeon engagement, and our growth opportunities during our Q3 earnings call.”
– Hospitals that have ordered Symvess® increased 44% during the third quarter, from 34 at the end of the second quarter to 49 as of September 30, 2026.
– Commercial momentum continues to build, driven by expanding hospital orders and surgeon interest.
Get started
Create a free account to read the full story.